Slide 1: KemPharm Q1 2022 Results Call
| a KemPharm Q1 2022 Results Call May 12, 2022 Trademarks herein are held by their respective owners.
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, includin
Slide 3: Innovative pharmaceutical company for CNS and rare diseases
Innovative pharmaceutical company discovering and developing novel treatments for CNS and rare diseases
Slide 4: KemPharm: Q1 2022 and Recent Highlights
KemPharm: Q1 2022 and Recent Highlights ¥ Continuing efforts to build a highly differentiated pipeline of developmentassets v Focusedon high-value areas with significant unmet needs in CNS/rare disease with Pipeline potential to internally commercialize v KP1077 IND for IH submitted to FDA v Phase 2
Slide 5: Pipeline of Product Candidates with Substantial Milestones in 2022 and Beyond
Pipeline of Product Candidates with Substantial Milestones in 2022 and Beyond 1g of Next Milestone Product Candidate Phase of Development Rare Sleep Disorders Idiopathic KP1077 Phase 2 2H 2022 Hypersomnia (IH) Narcolepsy KP1077 Phase 2 To follow IH trial start Type | and Il Sleep Disorders TBD Nparu
Slide 6: KP1077 Product Candidate Overview
KP1077 Product Candidate Overview + 100% Serdexmethylphenidate (SDX) productwith multiple dosing options depending on patient needs o Dosed either QD (1x daily at bedtime) or BID (2x daily at bedtime and upon waking) + Features and benefits already demonstrated: o SDX has already been designated C-I
Slide 7: KP1077: Addressing Cardiovascular Stimulant Comorbidities
KP1077: Addressing Cardiovascular Stimulant Comorbidities + Many comorbidities and patient demographics complicate treatment, including cardiovascular issues o Brain fog in IH is so debilitating that current, tolerable stimulant treatment doses are inadequate: = The ability to dose higher with fewer
Slide 8: Financial Update
Financial Update
Slide 9: Q1 2022 Results; Financial Position is a Source of Strength
Q1 2022 Results; Financial Position is a Source of Strength Income Statement Details for Q1 2022: * Q1 2022 revenue of $4.0M, derived primarily from consulting services fees, royalties, anda success fee from Corium related to FDA approval of its product, ADLARITY * Q1 2022 net loss attributable to c
Slide 10: Upcoming Clinical, Reg and BD Milestones Create Potential Near-Term Value
Upcoming Clinical, Reg and BD Milestones Create Potential Near-Term Value Milestone Q12022 Q2 2022 Q3 2022 Q4 2022 Q12023 Q2 2023 KP1077 for IH Type B meeting with FDA IND filing/may proceed Phase 1 CV differentiation trial Phase 2 trial KP1077 for Narcolepsy Type B meeting with FDA IND filing Phase
Slide 11: KemPharm
ee | a KemPharm Leveraging our LAT® Prodrug Technology to Create Long-Term Value For additional information please contact: Jason Rando jrando@tiberend.com